Lorlatinib Is Active in ROS1-Positive Non–Small Cell Lung Cancer

Article navigation

Research Watch| January 09 2020

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2020

American Association for Cancer Research.

Cancer Discov (2020) 10 (1): 12.

Abstract

In a phase I/II trial, lorlatinib was safe and effective in ROS1-positive non–small cell lung cancer.

2020

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.